Shares of Apellis Pharmaceuticals APLS fell in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 73.25% year over year to ($2.72), which missed the estimate of ($1.70).
Revenue of $623,000 up by 0.00% year over year, which missed the estimate of $810,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Apellis Pharmaceuticals hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Aug 09, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/r7pkvgyz
Technicals
Company's 52-week high was at $73.00
Company's 52-week low was at $26.38
Price action over last quarter: Up 28.52%
Company Description
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
